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Abstract 
Invasive aspergillosis (IA) is a major threat for the outcome of allogeneic stem-cell 
transplantation (allo-SCT). Despite presenting similar degrees of immunosuppression, 
not all individuals at-risk ultimately develop infection. Therefore, the traditional view of 
neutropenia as a key risk factor for aspergillosis needs to be accommodated within new 
conceptual advances on host immunity and its relationship to infection. Polymorphisms 
in innate immune genes, such as those encoding TLRs, cytokines and cytokine 
receptors, have recently been associated with susceptibility to IA in allo-SCT recipients. 
This suggests that understanding host–pathogen interactions at the level of host genetic 
susceptibility will allow the formulation of new targeted and patient-tailored antifungal 
therapeutics, including improved donor screening. 
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Introduction 
Invasive infections by Aspergillus moulds are associated with high rates of morbidity 
and mortality, particularly among patients with hematological malignancies, prolonged 
neutropenia, treated with corticosteroids, or undergoing stem-cell or solid organ 
transplantation [1]. Although immunocompetent and nonatopic subjects are fairly 
resistant to Aspergillus infections, A. fumigatus is associated with a wide spectrum of 
diseases in humans, ranging from allergic syndromes to more severe forms of invasive 
disease [2]. These considerations imply that only certain host circumstances render the 
fungus pathogenic or innocuous to the host [3]. As a matter of fact, the exposure to 
Aspergillus is ubiquitous, and there is no evidence that isolates causing invasive 
infection are genetically or phenotypically distinct [4]. 
The most important risk factor for invasive aspergillosis (IA) has historically 
been neutropenia. However, it is not clear why some patients with comparable levels of 
apparent immunocompromise develop disease and others do not. Additionally, stem-cell 
transplant recipients have reduced rates of neutropenia-related infections and increased 
frequency of late-onset infections, concomitant with the occurrence of graft-versus-host 
disease (GVHD) [5)]. These findings, together with the incidence of aspergillosis in 
non-neutropenic patients [2, 6], attest to the importance of specific defects in both 
innate and adaptive immune mechanisms to the pathogenesis of the infectious process 
[7-9]. 
Since allogeneic stem-cell transplantation (allo-SCT) dramatically impairs 
various layers of the immune system, subtle defects in the immune response could 
become clinically significant. On the contrary, in healthy individuals, the redundancy of 
the different immune pathways could easily camouflage such immune deficiencies. In 
this regard, over the last few years, significant advances into the genetic basis of IA 
occurring in the allo-SCT setting have been made (Table 1), being now clear that host 
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genetic variants determine disparate immune responses to the fungus, ultimately 
contributing to different degrees of susceptibility to infection [10]. 
 
The multi-faceted host immune response to Aspergillus fumigatus 
Although fungi are not mere passive bystanders in the infectious process, compelling 
evidence points to the mammalian immune system as the most important determinant of 
the host-fungus interaction. Host defense mechanisms against Aspergillus are numerous 
and range from relatively primitive and constitutively expressed non-specific defenses 
to sophisticated adaptive mechanisms induced specifically during infection [11]. These 
two arms of the immune system are linked through a variety of cross-regulatory 
pathways, the integration of which provides for the host the complex arsenal of effector 
mechanisms for defense. 
Among the multiple effector mechanisms of the innate immune system, resident 
alveolar macrophages have long been recognized as the first line of defense against 
Aspergillus, preventing hyphal germination and the consequent activation of 
inflammatory responses against the fungus [12].  In contrast, polymorphonuclear cells 
(PMNs) are the predominant immune cells in the acute stage of infection. PMNs may 
act as “double-edged swords”, as they are essential for pathogen eradication, but a 
disproportionate release of oxidants and proteases may also be responsible for injury to 
the lung [13]. This implies that tight regulatory mechanisms are required to balance 
protection and immunopathology for efficient control of the fungus. 
The innate immune response to fungi is based on a restricted number of 
receptors, the pattern recognition receptors (PRRs), which play important roles in 
manipulating the immune response against the fungus, improving or decreasing the 
intensity of the inflammatory reactions often intended to sterilize the host to avoid 
infection. Among the signaling PRRs, the Toll-like receptor (TLR) family is 
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undoubtedly involved in cell activation upon contact with pathogens [14]; specifically, 
TLR2, TLR4 and TLR9 have been implicated in host defense against A. fumigatus [13, 
15-18]. It is of interest that signaling through TLR2 and TLR4 in PMNs is associated 
with the induction of distinct activation programs, eventually culminating in the 
occurrence of different patterns of fungal clearance and inflammatory pathology [13, 
15]. On the other hand, A. fumigatus is also capable of subverting the host’s 
inflammatory response through the attenuation of TLR2- and TLR4-mediated 
proinflammatory responses, therefore leading to an immunosuppressive effect 
eventually facilitating invasiveness [19]. 
Although the signaling pathways elicited by TLRs are known to be essential in 
controlling fungal infection [15], recent studies have also highlighted the pivotal role of 
C-type lectin receptors, in particular dectin-1, in the immune response to A. fumigatus 
[20]. In fact, TLRs and dectin-1, alone or synergistically, can modulate the induction of 
Th1- and Th17-polarizing cytokines in response to the fungus [21], demonstrating that 
the involvement of innate immune receptors other than TLRs may also be required to 
promote adequate immune responses against A. fumigatus. 
 
TLR4 deficiency triggers paradoxical effects in invasive aspergillosis 
There is now undeniable evidence that genetic variants within recognition molecules 
involved in innate immunity may account, in part, for the inherited differences in human 
susceptibility to infection [22]. Given the broad effect of TLRs on immunity [14], their 
function in human disease has been investigated largely by comparing the incidence of 
disease among individuals with different polymorphisms in genes that participate in 
TLR signaling. Accordingly, growing amounts of data suggest that the ability of certain 
individuals to properly respond to TLR ligands may be impaired by polymorphisms in 
TLR genes, resulting in an altered susceptibility to, or course of, infectious or 
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inflammatory disease [23]. Most studies so far have focused on the highly polymorphic 
TLR4 gene, in which two co-segregated missense polymorphisms – D299G and T399I – 
have been described to compromise the extracellular ligand-binding domain of TLR4 
[24]. These variants have been linked with blunted airway [25] and systemic 
inflammatory responses [26] to inhaled lipopolysaccharide (LPS) in adults and 
attenuated LPS-induced responses in primary airway epithelial cells [25]. Interestingly, 
the D299G substitution was found to have a greater functional impact compared with 
the T399I genotype [25]. 
One of the first studies investigating the functional consequences of TLR4 
polymorphisms in aspergillosis described an increased frequency of the chronic form of 
pulmonary aspergillosis, chronic cavitary pulmonary aspergillosis (CCPA), among 
D299G carriers [27]. In CCPA patients, the fungus is able to grow in pre-formed lung 
cavities, therefore escaping immune surveillance. Considering that subjects harboring 
the D299G polymorphism have an additional defect in TLR4 function, the increased 
susceptibility observed is likely due to an extensive impairment in fungal recognition. 
Accordingly, Tlr4-deficient mice were also found to be highly susceptible to 
aspergillosis, in most part due to the inability to effectively clear the fungus [13]. 
In the stem-cell transplantation setting, the D299G polymorphism in TLR4 was 
also found to increase susceptibility to IA in allo-SCT recipients from unrelated donors 
[28]. The fact that a previous study failed to associate the same donor polymorphism 
with IA in allo-SCT patients [29] further stresses that the contribution of the D299G 
polymorphism may depend on the type of transplant and associated clinical variables. In 
this regard, we have recently described an association between donor D299G and 
colonization by A. fumigatus, but not invasive disease, in a cohort of T-cell-depleted 
transplant recipients from related donors [30]. Therefore, fungal colonization may not 
predict susceptibility to infection in the presence of D299G, at least in this particular 
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transplant setting. The contribution of this polymorphism to colonization by A. 
fumigatus could be explained by the fact that an abnormal TLR4 extracellular domain 
could be hampering its function by disrupting microbial recognition, eventually leading 
to fungal escape from immune surveillance (Fig. 1). However, TLR4 polymorphisms 
have also been shown to display a protective effect from hyper-inflammatory diseases, 
including atherosclerosis and related conditions [31]. Therefore, the failure to recognize 
the fungus may be compensated by the lack of an exuberant inflammatory response to it 
which may ultimately be harmful to the host. In this regard, we have found that a hyper-
inflammatory state, more than the fungus itself, may contribute to susceptibility to 
aspergillosis and other fungal infections [32]. Thus, by limiting the inflammatory 
response to the fungus, the D299G polymorphism could contribute to resistance to 
aspergillosis, despite evidence of fungal growth. Interestingly, the D299G 
polymorphism was recently shown to have a unique distribution with high prevalence in 
Africa and low prevalence in Europe, with the authors arguing that the benefit from 
reduced inflammation during malaria in Africa might have been counter-selected due to 
lack of inflammation in response to bacterial infections [33]. 
Although TLR4 has been representing the cornerstone of genetic variability to 
aspergillosis in the last few years, polymorphisms in other TLRs have also been linked 
with susceptibility to Aspergillus. In particular, a common polymorphism in the TLR9 
promoter (T-1237C) has been shown to predispose to the allergic form of pulmonary 
aspergillosis, allergic bronchopulmonary aspergillosis (ABPA) [27]. It is worth 
mentioning that we found this polymorphism to lead to an increase in TLR9 gene 
expression in human mononuclear cells that could be further sustained upon TLR9 
engagement, presumably resulting in a gain-of-function of the receptor (Rodrigues F, 
unpublished data). This observation is consistent with a role for TLR9 in response to 
allergy since Tlr9-deficient mice have been shown to be more resistant to induced 
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allergenic stimuli [34]. In addition, PMNs from these mice had an increased capacity to 
kill conidia and damage Aspergillus hyphae [13], therefore arguing for a detrimental 
role of this TLR9 polymorphism and consequent enhancement of TLR9 function in 
allergic aspergillosis. 
 
IL-23 and IL-17 have a largely detrimental role in aspergillosis 
Despite TLRs being proved to be crucial for detecting infection and activating the 
innate and adaptive immune systems, sustained TLR stimulation can result in chronic 
inflammation and is also associated with the development of certain autoimmune 
diseases [35]. In the last two decades, the immunopathogenesis of aspergillosis and 
associated inflammatory diseases has been explained primarily in terms of Th1/Th2 
balance [11, 36]. Until recently, CD4+ Th1 cells were considered responsible for the 
development of inflammatory responses to Aspergillus that were mediated by IL-12p70, 
the key cytokine driving Th1-cell differentiation. The discovery of the IL-12 cytokine-
family member IL-23 has led to a re-evaluation of this conceptual framework [37]. IL-
23, although not directly involved in Th17 differentiation, plays an important role in 
maintaining Th17 effector function [38]. Several experimental studies and clinical 
investigations confirmed that IL-23-driven Th17 cells, rather than the Th1-cell subset, 
mediate the inflammatory responses of autoimmune or infectious origin [32, 39]. In 
addition, both IL-23 and the Th17 pathway correlate with disease severity and 
immunopathology in diverse infections [40-41], suggesting that IL-12 and IL-23 have 
distinct roles in promoting antimicrobial immune responses and diseases in vivo. 
We have recently demonstrated that IL-17 has a largely detrimental role in 
aspergillosis in non-immunosuppressed mice, since it hampered neutrophil-mediated 
killing of A. fumigatus and the in vivo clearance of the fungus [41]. In addition, 
blockade of IL-23 and IL-17 greatly increased antifungal resistance, as judged by the 
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decreased fungal growth in the relevant target organs and the ameliorated signs of 
inflammation, both clinically and at the tissue level [41]. Thus, despite the important 
role in regulating PMN homeostasis and recruitment [42], IL- 23 and IL-17, by 
subverting the tolerogenic program of PMNs, may promote pathogen growth and 
infection as a result of the induced inflammatory pathology. In this regard, in a mouse 
model of chronic granulomatous disease, we have recently found that down-regulation 
of IL-23 promoted by exogenous administration of pentraxin 3 (PTX3) restored 
antifungal resistance and restrained the inflammatory response to the fungus through the 
limited expansion of IL-17-producing γδ T-cells and the emergence of Th1/Treg 
responses with minimum pathology [43]. Altogether, these results may serve to 
accommodate the paradoxical association of chronic inflammatory responses with 
intractable forms of fungal infection, where fungal persistence occurs in the face of an 
ongoing inflammation. 
The ability of IL-17 to promote fungal germination further stresses its potential 
negative role in the immune responses against A. fumigatus [44]. Therefore, the function 
of the Th17 pathway may go beyond its ability to promote inflammation and subvert 
antimicrobial immunity by also having a direct action on fungal morphology and 
virulence. This may translate in concomitant Th2 cell activation, known to be strictly 
dependent on high levels of hyphal growth [45], and further prevent Th1 functioning. 
Thus, the Th17 pathway may contribute to the pathogenesis of fungal infections, 
occurring in a fungus-autonomous fashion at sites of infection. 
 
Genetic impairment of IL-23 signaling protects from invasive aspergillosis 
Polymorphisms in cytokine genes can influence immune responses and inflammation, 
thereby affecting susceptibility to aspergillosis in allo-SCT recipients [46]. However, 
the role of polymorphisms in genes from the IL-23/Th17 inflammatory pathway in 
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aspergillosis has only recently been addressed [47]. It has already been shown that the 
R381Q variant in IL23R confers protection against a number of immune-mediated 
diseases, such as inflammatory bowel disease [48] and psoriasis [49], but also against 
GVHD in recipients of hematopoietic cells from HLA-identical donors [50]. Although 
the genetic findings have been thoroughly replicated, much less is known about the 
functional consequences of this variant. A recent study demonstrated that the protective 
effects displayed by the R381Q polymorphism in IL23R were due to a deficient 
activation of IL-23-driven Th17 responses [51]. In vitro committed effector Th17 cells 
derived from subjects harbouring the R381Q protective allele stimulated with IL-23 
were shown to have impaired production of IL-17A compared to wild-type individuals 
[51]. Interestingly, IL-23 stimulation of highly purified naïve T-cells did not result in 
any difference whatsoever between R381Q genotypes [51], suggesting that the 
consequences of the polymorphism may be exclusively reflected in the function of 
already differentiated Th17 cells. 
In T-cell-depleted allo-SCT recipients, we found that donor R381Q was 
associated with strong protection from IA and patient R381Q with improved overall 
survival [47] (Fig. 2). Strikingly, none of the patients carrying the R381Q 
polymorphism enrolled in the study developed aspergillosis. These findings are 
consistent with the protective effects of IL-23 signaling attenuation in experimental 
aspergillosis [41]. However, a set of polymorphisms in the IL17A and IL17F genes were 
not associated with susceptibility to IA in allo-SCT recipients [47], a finding suggesting 
that further studies are needed to define cellular and molecular mechanisms by which 
protection from aspergillosis is conferred by the disruption of the IL-23/Th17 axis. 
 The fact that donor R381Q also increased the risk of cytomegalovirus infection 
[47], while being consistent with the enhancing role of IL-23 of antiviral immunity [52], 
indicates that Aspergillus more than viral infection may impact on survival, at least in 
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the T-cell-depleted transplantation setting. Although the R381Q polymorphism could 
arguably influence survival by modifying the incidence of disease relapse or GVHD, no 
beneficial effects on relapse or GVHD were found at all [47]. 
 
Immunogenetics: from bench to bedside 
Although the dissection of complex genetic traits modulating susceptibility to 
aspergillosis is complex, the contribution of host genetics may hold the key to elucidate 
new risk factors for these severe, often fatal diseases. In this sense, new conceptual 
advances on the knowledge of host immunity need to be accommodated also from an 
immunogenetic point of view. 
It is interesting that the genetic bases for susceptibility to human disease may 
also be evaluated by the screening of inbred murine strains. Recently, this approach was 
performed using an immunocompromised mice model of IA [53]. Through a haplotype-
based computational genetic analysis of survival data, the gene encoding plasminogen 
(PLG) was recently identified as a suitable candidate for susceptibility to Aspergillus. 
Consequently, a functional polymorphism in human PLG was reported to affect the risk 
of developing IA in allo-SCT recipients [53]. Besides shedding light into the role of the 
fibrinolytic system in the pathogenesis of IA, this approach identified a novel, 
biologically plausible candidate gene, validating its future use in the identification of 
less obvious disease-related genes. 
Considering the key role played by many genetic polymorphisms at the host–
fungus interface, further large-scale translational and clinical studies are needed to 
corroborate the data obtained from human cohorts. The modulation of host immune 
responses has been regarded as a potential therapeutic avenue with promising impact 
also on the treatment of fungal infections. We have recently reported that intranasal 
administration of a small interference RNA (siRNA) targeting the inflammatory 
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PI3K/Akt/mTOR pathway rendered mice protection from experimental aspergillosis 
through attenuation of the inflammatory pathology [54]. The promising application of 
siRNA therapeutics, together with the awareness of the immunogenetic profile of each 
individual at-risk, including those subjected to allo-SCT, could prove useful to the 
design of fungal vaccines capable of targeting the appropriate signaling pathways and 
the development of therapeutics that target inflammation in aspergillosis. 
In conclusion, understanding host–pathogen interactions at the level of host 
genetic susceptibility, together with the molecular and cellular bases affected, will allow 
the identification of potential therapeutic targets and the design of prophylactic 
strategies exerting control over the outcome of immune pathways. The genetic 
screening of at-risk patients may ultimately be used to individualize treatments through 
the formulation of new targeted and patient-tailored antifungal therapeutics, which are 
likely to improve the management and outcome of aspergillosis, particularly in the 
stem-cell transplantation setting. 
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Figure legends 
Fig.1 - The D299G polymorphism of TLR4 triggers paradoxical effects in invasive 
aspergillosis following stem-cell transplantation. 
 
Fig.2 – The genetic impairment of IL-23 signaling promoted by the R381Q 
polymorphism in IL23R protects from invasive aspergillosis. 
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Table 1. Human genetic association studies evaluating polymorphisms in immune genes and susceptibility to invasive 
aspergillosis in allogeneic stem-cell transplant recipients. 
Reference Gene Polymorphism/Haplotypes  Relevant findings 
Bochud et al. TLR4 D299G and T399I (S4 haplotype)  
An association between donor S4 haplotype and risk of IA was observed, especially 
if combined with CMV positivity (n=103 IA cases) 
Carvalho et al. TLR4 D299G *  Donor D299G was associated with fungal colonization (n=58), while susceptibility to IA was instead decreased among pre-colonized patients (n=34) 
Carvalho et al. IL23R R381Q  Donor R381Q displayed a protective effect from IA (n=25 IA cases) 
Granell et al. MBL2 O/O or LXA/O †  Donor MBL-low genotype (38% vs. 12%) was associated with a higher probability 
of IA (n=106 donor-patients sibling pairs) 
Granell et al. MASP2 D105G  Recipient D105G (67% vs. 14%) was associated with a higher probability of IA (n=106 donor-patient sibling pairs) 
Kesh et al. TLR1 and TLR6 R80T, N248S and S249P  
TLR1 R80T or combination of TLR1 N248S and TLR6 S249P from the recipient 
were associated with IA (n=22 IA cases) 
Mezger et al. CXCL10 C+11101T, C+1642G and A–1101G  Donor CXCL10 polymorphisms were associated with IA (n=81 IA cases) 
Seo et al. IL10 -1082A/-819C/-592C  Recipient ACC haplotype had a protective role from IA (n=105 patients; 9.9% IA 
cases) 
Zaas et al. PLG D472N  Risk of IA at day >40 after transplant was 5.6-fold higher in N/N vs. D/D recipients (n=83 IA cases) 
 
IA – invasive aspergillosis; CMV – cytomegalovirus; MBL – mannose-binding lectin. 
* D299G and T399I were always co-segregated. 
† O/O and LXA/O are MBL-low haplotypes. LX represents an MBL promoter haplotype. Variants D, B and C are collectively named O, while A indicates the wild-type. 
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The D299G polymorphism of TLR4 triggers paradoxical effects in invasive aspergillosis following 
stem-cell transplantation.  
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The genetic impairment of IL-23 signaling promoted by the R381Q polymorphism in IL23R protects 
from invasive aspergillosis.  
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